ATE337016T1 - Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen - Google Patents

Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Info

Publication number
ATE337016T1
ATE337016T1 AT00931720T AT00931720T ATE337016T1 AT E337016 T1 ATE337016 T1 AT E337016T1 AT 00931720 T AT00931720 T AT 00931720T AT 00931720 T AT00931720 T AT 00931720T AT E337016 T1 ATE337016 T1 AT E337016T1
Authority
AT
Austria
Prior art keywords
orally administered
bioavailability
compositions
increase
pharmaceutical compounds
Prior art date
Application number
AT00931720T
Other languages
English (en)
Inventor
Johannes Henricus Ma Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Res Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Ventures Ltd filed Critical Cancer Res Ventures Ltd
Application granted granted Critical
Publication of ATE337016T1 publication Critical patent/ATE337016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00931720T 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen ATE337016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30

Publications (1)

Publication Number Publication Date
ATE337016T1 true ATE337016T1 (de) 2006-09-15

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
AT00931720T ATE337016T1 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1749540B1 (de)
AT (2) ATE484295T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60030283T2 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PT1189637E (pt) * 1999-05-17 2007-01-31 Cancer Res Ventures Ltd Composições para melhorar a biodisponibilidade de fármacos administrados oralmente
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
WO2006012958A2 (en) * 2004-07-01 2006-02-09 The Netherlands Cancer Institute Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
EP1789128B1 (de) 2004-08-27 2018-05-09 STOCO 10 GmbH Elektronisch gesteuerte und ferngesteuerte tablette und system zur abgabe von mindestens einem medikament
EP1819392B1 (de) * 2004-11-29 2010-10-20 Koninklijke Philips Electronics N.V. Elektronisch gesteuerte tablette
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
US8990018B2 (en) * 2008-03-31 2015-03-24 MEDIMETRICS Personalized Drug Delivery B.V. Method of preparing a swallowable capsule comprising a sensor
JP5627569B2 (ja) 2008-04-30 2014-11-19 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッドＳｉｅｍｅｎｓ Ｍｅｄｉｃａｌ Ｓｏｌｕｔｉｏｎｓ ＵＳＡ，Ｉｎｃ． 新規基質に基づくｐｅｔ造影剤
CN102065930B (zh) * 2008-06-19 2013-05-22 皇家飞利浦电子股份有限公司 用于在潮湿环境下传递粉末状药物的装置
JP5670326B2 (ja) * 2008-06-25 2015-02-18 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 複数の薬剤リザーバを有する電子ピル
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
DK0569380T3 (da) * 1991-01-11 1997-12-22 Glaxo Lab Sa Acridinderivater
US5663179A (en) * 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
RU2157687C2 (ru) 1994-10-05 2000-10-20 Глаксо Вэллкам Инк. Фармацевтические составы для парентерального введения, содержащие n-{4-[2-(1,2,3,4-тетрагидро-6,7-диметокси-2-изохинолинил)-этил]-фенил]-9,1 0-дигидро-5-метокси-9-оксо-4-акридинкарбоксамид
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
KR100615783B1 (ko) 1997-05-27 2006-08-25 아이박스 리서치 인코포레이티드 탁산 치료를 받고 있는 인체를 제외한 포유동물의 과민증 또는 알러지 반응을 경감시키기 위한 방법 및 약학적 키트
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2319715C (en) * 1998-02-05 2012-08-07 University Of Maryland, Baltimore Breast cancer resistance protein (bcrp) and the dna which encodes it
AU764370B2 (en) 1998-06-18 2003-08-14 George Washington University, The Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
EA002917B1 (ru) 1998-08-05 2002-10-31 Авентис Фарма С.А. Применение хлорида натрия для уменьшения вторичных желудочно-кишечных эффектов, обусловленных применением производных камптотецина
PT1189637E (pt) * 1999-05-17 2007-01-31 Cancer Res Ventures Ltd Composições para melhorar a biodisponibilidade de fármacos administrados oralmente
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
CY1105795T1 (el) 2011-02-02
US20020128282A1 (en) 2002-09-12
ES2270834T3 (es) 2007-04-16
EP1189637A2 (de) 2002-03-27
AU4955200A (en) 2000-12-05
DE60045114D1 (de) 2010-11-25
EP1749540B1 (de) 2010-10-13
EP1749540A3 (de) 2007-05-30
EP1189637B1 (de) 2006-08-23
DE60030283D1 (de) 2006-10-05
DK1189637T3 (da) 2006-12-11
US7030132B2 (en) 2006-04-18
ATE484295T1 (de) 2010-10-15
US20060128743A1 (en) 2006-06-15
EP1749540A2 (de) 2007-02-07
DE60030283T2 (de) 2007-09-20
PT1189637E (pt) 2007-01-31
WO2000069390A3 (en) 2001-12-13
WO2000069390A2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
ATE337016T1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
DE69526428D1 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE292453T1 (de) Antivirale arznei
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
ITMI992736A0 (it) Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi
GT200100223A (es) Composiciones hidroliticamente inestables.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1189637

Country of ref document: EP